checkAd

    HIV-Schnelltests mit Orasure -Unentdeckte Perle- - 500 Beiträge pro Seite

    eröffnet am 28.04.03 09:42:28 von
    neuester Beitrag 26.06.03 11:55:19 von
    Beiträge: 7
    ID: 725.805
    Aufrufe heute: 0
    Gesamt: 1.226
    Aktive User: 0


     Durchsuchen

    Begriffe und/oder Benutzer

     

    Top-Postings

     Ja Nein
      Avatar
      schrieb am 28.04.03 09:42:28
      Beitrag Nr. 1 ()
      Am 29.04.2003 kommen die Zahlen für das erste Quartal und die sollen sehr sehr gut ausfallen. Zum ersten Mal könnte es in diesem Jahr ein Gewinn geben.

      Fakten:
      Wartezeit auf das Ergebnis des HIV-Tests von Orasure 20 Min
      Genauigkeit 99,6%
      2003 angepeilter Gewinn von 8 cent je Aktie
      2004 angepeilter Gewinn von 18 cent je Aktie
      Staatliche Bestellungen Buget für AIDS.Präventivmaßnahmen in den usa in 2004 16 Milliarden USD
      60.000 Kliniken werden hierdurch beim Kauf von OrasureTest bezuschußt
      Die NAvy orderte 10.000 Tests
      Übernahmephantasie durch Abbot
      Charttechnischer Wiederstand bei USD 7,14 nicht mehr weit und durch gute zahlen könnte dieser Signifikant durchbrochen werden.

      Homepage www.orasure.com



      BETHLEHEM, Pa.--(BUSINESS WIRE)--April 25, 2003--OraSure Technologies, Inc. (Nasdaq NM:OSUR - News) announced today the execution of an exclusive distribution agreement with Medtech Holdings, Inc. pursuant to which OraSure will manufacture and supply, and Medtech will purchase, the Company`s cryosurgical wart removal product for distribution in the over-the-counter ("OTC") market in the United States and Canada.

      The product will be manufactured and sold under Medtech`s Compound W® and Freeze OFF® trademarks, and will be made available for retail purchase in drug stores, supermarkets and mass merchandisers.

      "After many years of successfully selling a similar cryosurgical wart removal system for professional use under the Histofreezer® trade name, we are pleased to partner with Medtech on a cryosurgical product ideally suited for the consumer market," said Mike Gausling, President and CEO of OraSure Technologies. "Over the past ten years, at least 40 million wart treatments have been sold to physicians with our Histofreezer® cryosurgical wart removal product. We believe that expanding into the OTC market is a logical market extension and Medtech, with its family of Compound W® wart removal products, is the ideal partner to distribute Freeze OFF® in the consumer marketplace."

      Earlier this year, OraSure applied for and secured clearance from the U.S. Food and Drug Administration to sell this product in the OTC market in the United States for the treatment of common and plantar warts only. The Freeze OFF® product will consist of a small aerosol canister containing a refrigerant, and a package of 12 foam buds attached to hollow tube applicators.

      In order to treat a common or plantar wart, the foam bud applicator is inserted into the nozzle of the canister and the refrigerant is applied to the affected area in order to freeze the wart. The product is expected to be available by mid summer.

      About OraSure Technologies

      OraSure Technologies develops, manufactures and markets oral fluid specimen collection devices using proprietary oral fluid technologies and diagnostic products, including immunoassays and other in vitro diagnostic tests and other medical devices.

      These products are sold in the United States and certain foreign countries to government agencies, clinical laboratories, physicians` offices, hospitals, commercial and industrial entities, and various distributors.

      OraSure Technologies is the leading supplier of oral fluid collection devices and assays to the life insurance industry and public health markets for the detection of antibodies to HIV-1 and supplies oral fluid testing solutions for drugs of abuse testing.

      In addition, OraSure sells the Histofreezer® wart removal system to professional markets in the United States and many foreign countries, for the treatment of warts and other benign skin lesions. For more information on OraSure, please go to www.orasure.com.

      This press release contains certain forward-looking statements, including with respect to sales, markets and products. Actual results could be significantly different.

      Factors that could affect results include the ability to market products; impact of competitors, competing products and technology changes; ability to develop, commercialize and market new products; market acceptance of oral fluid testing products and other products; ability to fund research and development and other projects and operations; ability to obtain and timing of obtaining necessary regulatory approvals; ability to develop product distribution channels; uncertainty relating to patent protection and potential patent infringement claims; ability to enter into international manufacturing agreements; obstacles to international marketing and manufacturing of products; ability to sell products internationally; loss or impairment of sources of capital; exposure to product liability and other types of litigation; changes in international, federal or state laws and regulations; changes in relationships with strategic partners and reliance on strategic partners for the performance of critical activities under collaborative arrangements; changes in accounting practices or interpretation of accounting requirements; customer inventory practices and consolidations; equipment failures and ability to obtain needed raw materials and components; the impact of terrorism and civil unrest; and general business, political and economic conditions.

      These and other factors are discussed more fully in the Securities and Exchange Commission filings of OraSure Technologies, including its registration statements, its Annual Report on Form 10-K for the year ended December 31, 2002. Although forward-looking statements help to provide complete information about future prospects, readers should keep in mind that forward-looking statements may not be reliable.

      The forward-looking statements are made as of the date of this press release and OraSure Technologies undertakes no duty to update these statements.



      --------------------------------------------------------------------------------
      Contact:
      OraSure Technologies, Inc.
      William E. Bruckner, 610/882-1820
      or
      OraSure Technologies, Inc.
      Financial Contact:
      Ronald H. Spair, 610/882-1820



      --------------------------------------------------------------------------------
      Source: OraSure Technologies, Inc.
      Avatar
      schrieb am 28.04.03 15:01:58
      Beitrag Nr. 2 ()
      so unbekannt ist Sie nun auch wieder nicht. Vielleicht hier aber nicht drüben.

      Geschätzte Zahlen für 1Q sind gerade raus: $8.50M -0.04

      cu
      Avatar
      schrieb am 29.04.03 01:26:01
      Beitrag Nr. 3 ()
      OraQuick Rapid HIV-1 Antibody Test is Highlighted in New CDC HIV Prevention Initiative

      BETHLEHEM, Pa., Apr 28, 2003 (BUSINESS WIRE) --

      -CDC Recommends Use of Rapid Testing as Part of Comprehensive HIV
      Testing Strategy-

      OraSure Technologies, Inc. (Nasdaq NM:OSUR), the market leader in oral fluid diagnostics, announced today that the Centers for Disease Control and Prevention ("CDC") stated that simple, rapid HIV testing would be a key component to its new HIV testing initiative announced by the CDC on Thursday, April 17, 2003, in the CDC`s Morbidity and Mortality Weekly Report ("MMWR") (April 18, 2003 / Vol. 52 / No. 15), and recognized the OraQuick (R)Rapid HIV-1 Antibody Test as the only CLIA (Clinical Laboratory Improvements Amendments of 1988) waived rapid HIV-1 test approved by the FDA.

      The new CDC initiative, entitled "Advancing HIV Prevention: New Strategies for a Changing Epidemic," is aimed at making HIV tests a more routine part of medical practice for pregnant women and the estimated 200,000 people in the United States who currently have the HIV virus but may be unaware that they are infected. The initiative expands on current HIV prevention strategies and encourages the more widespread use of rapid HIV testing.

      "We applaud the CDC`s new HIV testing initiative and are eager to continue working in partnership with the CDC to make rapid HIV testing available to all who need it," said Mike Gausling, President and Chief Executive Officer of OraSure Technologies. "As the only CLIA waived, rapid, point-of-care HIV-1 test, OraQuick(R) will be crucial for HIV testing in non-traditional settings, where simplicity and mobility are critical factors."

      "This new initiative is exciting and it capitalizes on new, rapid testing technologies; provides us the opportunity to reduce barriers to testing; enhances prevention services; and continues to prevent mother-to-child HIV infections," said Harold Jaffe, M.D., director of CDC`s National Center for HIV, STD, and TB Prevention. (CDC Press Release, 4/17/2003)

      The CDC has identified $35 million to support the new HIV testing strategy. As part of this comprehensive initiative, the CDC announced that in 2003 it will fund new demonstration projects using OraQuick(R) to increase access to early diagnosis and referral for treatment and prevention services in high-HIV prevalence settings, including correctional facilities. (MMWR, April 18, 2003)

      The initiative has four parts, and will be implemented by several agencies working together within the Department of Health and Human Services. It includes making HIV testing a routine part of medical care; creating new models for diagnosing HIV infections outside medical settings; preventing new infections by working with people diagnosed with HIV and their partners; and further decreasing mother-to-child HIV transmission by incorporating HIV testing in the routine battery of prenatal tests.

      On Thursday, April 24, 2003, the CDC hosted a satellite broadcast and web cast entitled, "Update on Rapid Testing for HIV." The 2-hour forum was co-sponsored by the CDC and the Public Health Training Network, and described rapid tests for HIV including availability, administration, benefits and limitations; implementation considerations for counseling and testing; confirmatory testing for positive test results; quality assurance and training; and resources for updates on rapid testing. The broadcast featured presentations, interviews and panel responses to audience questions and a replay may be accessed through a link at http://legacy.cdcnpin.org/broadcast/current/2003/0424/start.…

      OraQuick(R) is the first FDA-approved rapid, point-of-care test designed to detect antibodies to HIV-1 in finger-stick whole blood within approximately 20 minutes. OraSure received FDA approval of the OraQuick (R)test on November 7, 2002. On January 31, 2003, OraSure received a CLIA waiver for the test, permitting its use by more than 180,000 sites in the United States, including outreach clinics, community-based organizations and physicians` offices.

      About OraSure Technologies

      OraSure Technologies develops, manufactures and markets oral fluid specimen collection devices using proprietary oral fluid technologies and diagnostic products, including immunoassays and other in vitro diagnostic tests and other medical devices. These products are sold in the United States and certain foreign countries to various distributors, government agencies, clinical laboratories, physicians` offices, hospitals, and commercial and industrial entities.

      OraSure Technologies is the leading supplier of oral-fluid collection devices and assays to the life insurance industry and public health markets for the detection of antibodies to HIV-1. In addition, the Company supplies oral-fluid testing solutions for drugs of abuse testing. For more information on the Company, please go to www.orasure.com.

      Important Information

      This press release contains certain forward-looking statements, including with respect to sales, markets and products. Actual results could be significantly different. Factors that could affect results include the ability to market products; impact of competitors, competing products and technology changes; ability to develop, commercialize and market new products; market acceptance of oral fluid testing or other products; ability to fund research and development and other projects and operations; ability to obtain and timing of obtaining necessary regulatory approvals; ability to develop product distribution channels; uncertainty relating to patent protection and potential patent infringement claims; ability to enter into international manufacturing agreements; obstacles to international marketing and manufacturing of products; loss or impairment of sources of capital; exposure to product liability and other types of litigation; changes in international, federal or state laws and regulations; changes in relationships with strategic partners and reliance on strategic partners for the performance of critical activities under collaborative arrangements; changes in accounting practices or interpretation of accounting requirements; customer inventory practices and consolidations; equipment failures and ability to obtain needed raw materials and components; the impact of terrorism and civil unrest; and general business, political and economic conditions. These and other factors are discussed more fully in the Securities and Exchange Commission filings of OraSure Technologies, including its registration statements and its Annual Report on Form 10-K for the year ended December 31, 2002. Although forward-looking statements help to provide complete information about future prospects, readers should keep in mind that forward-looking statements may not be reliable. The forward-looking statements are made as of the date of this press release and OraSure Technologies undertakes no duty to update these statements.

      SOURCE: OraSure Technologies, Inc.

      OraSure Technologies, Inc.
      Investor Contact:
      Ronald H. Spair, 610/882-1820
      Investorinfo@orasure.com
      www.orasure.com
      or
      OraSure Technologies, Inc.
      Media Contact:
      William Bruckner, 610/882-1820
      wbruckner@orasure.com

      http://www.businesswire.com

      Today`s News On The Net - Business Wire`s full file on the Internet
      with Hyperlinks to your home page.


      Copyright (C) 2003 Business Wire. All rights reserved.
      Avatar
      schrieb am 29.04.03 14:53:53
      Beitrag Nr. 4 ()
      Der Erfolg mit HIV- Schnelltests war nie besonders gross. Ob calypte oder Trinity Biotech und andere.Warum sollte es hier anders sein??? Esgibt keinen Grund anzunehmen das diese Firma erfolgreicher sein sollte!!Von billigen und einfachen wie auch genauen Tests gibt es mitlerweile mehrere. Ob Urin, Blut oder Speichelprobe alles auf dem Markt erhältlich!

      gruss meislo
      Avatar
      schrieb am 30.04.03 09:32:14
      Beitrag Nr. 5 ()
      Tuesday , April 29, 2003 17:16 ET
      QUARTER RESULTS

      OraSure Technologies, Inc (NASDAQ NM: OSUR) reported Q1 results ended March 2003. Q1 Revenues were $8.61M; +11.38% vs yr-ago; BEATING revenue consensus estimates by +1.29%. Q1 EPS was (3c); +25.00% vs yr-ago; BEATING EPS consensus estimates by +25.00%.

      Trading Spotlight

      Anzeige
      EV Minerals Corporation
      0,0350EUR 0,00 %
      Massive 1.460% Rallye “ante portas”?!mehr zur Aktie »
      Avatar
      schrieb am 16.05.03 10:35:23
      Beitrag Nr. 6 ()
      Hier könnte evtl was neues rauskommen zu Orasure. Denke das ist auch der Grund für den Kursanstieg bis knapp USD 7,00 von gestern.




      OraSure Technologies to Host HHS Deputy Secretary Claude Allen at Event on HIV Testing and Prevention
      Thursday May 15, 11:52 am ET


      BETHLEHEM, Pa.--(BUSINESS WIRE)--May 15, 2003--Claude Allen, Deputy Secretary of the U.S. Department of Health and Human Services, and other leading federal healthcare officials will offer remarks on HIV testing and prevention strategies in the United States and abroad, on Monday, May 19, 2003, from noon to 1:00 p.m. EDT, at the headquarters of OraSure Technologies, Inc. (Nasdaq:OSUR - News) in Bethlehem, PA.

      The event, hosted by OraSure in recognition of the FDA`s recent approval of its OraQuick® Rapid HIV-1 Antibody Test, will acknowledge the work of federal, state and local agencies in their initiatives on national and global HIV/AIDS prevention.

      Ambassador Jack Chow, M.D., Deputy Assistant Secretary for Health and Science, U.S. State Department, Dr. Joe O`Neill, Director, White House Office of National AIDS Policy, William H. Gimson, III, Chief Operating Officer, Centers for Disease Control and Prevention, Captain Maura Emerson, M.D., U.S. Navy, Military Sealift Command, and a representative from the office of U.S. Senator Arlen Specter are also scheduled to participate in the event.

      "The United States is committed to the fight against AIDS on a national and international level, and we will continue in our efforts to enhance prevention services across the nation," said Claude Allen, Deputy Secretary of the U.S. Department of Health and Human Services. "The introduction of new, rapid testing technologies, such as the OraQuick® Rapid HIV-1 Antibody Test, has enabled us to reduce barriers to testing and help increase the number of people who know their HIV status, helping to stop the spread of AIDS."

      Additionally, leading officials from the Presidential Advisory Council on HIV and AIDS (PACHA), the AIDS Healthcare Foundation, the Children`s AIDS Fund, the National Alliance of State and Territorial AIDS Directors (NASTAD), the Institute for Youth Development, and the National Minority AIDS Council will be in attendance.

      Members of the local community are also welcome to attend this event.

      "OraSure`s development of the OraQuick® test is a giant step in combating the global AIDS crisis," said Senator Arlen Specter. "With this test, people will be able to more easily and efficiently screen for HIV, which will help prevent those infected from passing the virus to others and allow them to more effectively treat their disease."

      "We are honored to host this event, bringing together so many people who play such a critical role in combating this global pandemic," said Mike Gausling, President and Chief Executive Officer of OraSure Technologies. "And, we are proud to continue working in partnership with the HHS, CDC and the Bush Administration to make rapid HIV testing available to all who need it."

      The following is a complete list of officials scheduled to participate in the event:

      Claude Allen, J.D., Deputy Secretary of the U.S. Department of Health and Human Services (HHS).
      Ambassador Jack Chow, M.D., Deputy Assistant Secretary for Health and Science, U.S. State Department.
      Joe O`Neill, M.D., Director, White House Office of National AIDS Policy.
      William H. Gimson, III, Chief Operating Officer, Centers for Disease Control and Prevention.
      A representative from the office of Senator Arlen Specter, United States Senator, Pennsylvania.
      Captain Maura Emerson, M.D., U.S. Navy Military Sealift Command.
      Dr. Jim Driscoll, Advisor, AIDS Healthcare Foundation; Member, Presidential Advisory Council on HIV/AIDS (PACHA).
      Anita Smith, Vice President, Children`s AIDS Fund; Member, PACHA.
      Shepard Smith, President, Institute for Youth Development.
      Debbie Rock, Executive Director, Baltimore Pediatric AIDS Program, Inc.; Member, PACHA.
      Dr. Beny Primm, Chairman, National Minority AIDS Council.
      Luciano Orsini, President, Philadelphia AIDS Consortium.
      Laura Hannen, Director, National Alliance of State and Territorial AIDS Directors.
      OraQuick® is the first FDA-approved rapid, point-of-care test designed to detect antibodies to HIV-1 in finger-stick whole blood within approximately 20 minutes. OraSure received FDA approval of the OraQuick (R)test on November 7, 2002.

      On January 31, 2003, OraSure received a CLIA (Clinical Laboratory Improvements Amendments of 1988) waiver for the test, permitting its use by more than 180,000 sites in the United States, including outreach clinics, community-based organizations and physicians` offices.

      About OraSure Technologies

      OraSure Technologies develops, manufactures and markets oral fluid specimen collection devices using proprietary oral fluid technologies and diagnostic products, including immunoassays and other in vitro diagnostic tests and other medical devices.

      These products are sold in the United States and certain foreign countries to various distributors, government agencies, clinical laboratories, physicians` offices, hospitals, and commercial and industrial entities.

      OraSure Technologies is the leading supplier of oral-fluid collection devices and assays to the life insurance industry and public health markets for the detection of antibodies to HIV-1. In addition, the Company supplies oral-fluid testing solutions for drugs of abuse testing. For more information on the Company, please go to www.orasure.com.



      --------------------------------------------------------------------------------
      Contact:
      OraSure Technologies, Inc.
      William Bruckner, 610/882-1820
      wbruckner@orasure.com
      Avatar
      schrieb am 26.06.03 11:55:19
      Beitrag Nr. 7 ()
      Orasure hat eine satte Aufwärtsbewegung in den letzten Tagen hinter sich die Widerstände bei 7,55 und 8 USD sind genommen. Nun sollte der Weg frei in richtung 10 USD sein ..... HIV-Schnelltest wurden in dem egstern zuende gehenden Biotechkongress lobenswert werwähnt. Schaut mal in die neusten Meldungen von Orasure !!!!


      Beitrag zu dieser Diskussion schreiben


      Zu dieser Diskussion können keine Beiträge mehr verfasst werden, da der letzte Beitrag vor mehr als zwei Jahren verfasst wurde und die Diskussion daraufhin archiviert wurde.
      Bitte wenden Sie sich an feedback@wallstreet-online.de und erfragen Sie die Reaktivierung der Diskussion oder starten Sie
      hier
      eine neue Diskussion.

      Investoren beobachten auch:

      WertpapierPerf. %
      -4,53
      -0,91
      +0,14
      0,00
      +0,59
      +0,21
      +0,66
      +0,42
      +0,20
      -2,90
      HIV-Schnelltests mit Orasure -Unentdeckte Perle-